Warner-Lambert still in Swiss-type pain in the UK
Following the guidance from the Court of Appeal, Mr Justice Arnold has ruled that some of the claims of Warner-Lambert's second medical use patent for the drug pregabalin are invalid, and that Actavis has not infringed two claims directed to the use of pregabalin
Warner-Lambert marketed, through Pfizer, the drug pregabalin under the trade mark Lyrica for the treatment of epilepsy, generalised anxiety disorder (non-patented indications) and neuropathic pain. The basic patent protection (European Patent No. 0 641 330), supplementary protection certificate (SPC/GB04/034) and...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.